Orthopaedic Surgery - Undifferentiated Sarcoma

Basics

Undifferentiated sarcoma is an uncommon:

High-grade malignant mesenchymal tumor

that may arise in:

Soft tissue

or

Bone.

Historically, many of these tumors were classified as:

Malignant fibrous histiocytoma

or

MFH.

In modern pathology, tumors previously placed in this category are often classified more specifically, with many high-grade soft-tissue lesions termed:

Undifferentiated pleomorphic sarcoma.

Primary Bone Disease

When the tumor originates in bone, it most commonly affects the:

Long bones.

Common sites include the:

Femur

Tibia

and other major:

Appendicular bones.

Tumor Behavior

Undifferentiated sarcoma is generally:

Highly aggressive

with substantial potential for:

Local recurrence

and

Hematogenous metastasis.

Classification

Several histologic subtypes have historically been described.

However, older subtype classifications have not consistently demonstrated important:

Prognostic value.

Prevention

There are no known measures that reliably prevent:

Primary undifferentiated sarcoma.

Epidemiology

The tumor can occur at:

Any age

but is most frequently diagnosed during the:

Fifth through seventh decades of life.

Sex

There is no strong sex predilection, although some series have reported a slight:

Male predominance.

Incidence

Primary undifferentiated sarcoma of bone is:

Rare.

Historical Bone-Tumor Series

One historical Mayo Clinic series recorded:

83 cases

representing approximately:

1% of primary bone tumors

in that institutional population.

Soft-Tissue Disease

Historically, MFH was regarded as one of the most common adult:

Soft-tissue sarcomas.

With modern immunohistochemical and molecular classification, many tumors formerly called MFH are now reassigned to more specific:

Sarcoma subtypes.

Risk Factors

Most cases arise without an identifiable:

Predisposing cause.

However, some develop secondarily in abnormal or previously treated:

Bone or soft tissue.

Paget Disease

Undifferentiated sarcoma may rarely arise in bone affected by:

Paget disease.

Bone Infarction

A malignant sarcoma may also develop within a chronic:

Bone infarct.

Radiation Exposure

Prior therapeutic radiation is an established risk factor for:

Radiation-associated sarcoma.

Such tumors typically develop after a:

Long latency period.

Secondary Tumors

Historical literature has suggested that up to approximately:

25% of cases

may arise secondarily in association with:

Pre-existing bone disease

or

Prior radiation.

The exact proportion varies between series and diagnostic eras.

Genetics

No single characteristic inherited genetic abnormality defines:

Undifferentiated sarcoma.

These tumors generally demonstrate complex:

Genomic abnormalities

rather than one pathognomonic mutation.

Etiology

The cause of most cases remains:

Unknown.

Diagnosis

The clinical presentation resembles that of other:

High-grade primary bone or soft-tissue sarcomas.

Signs and Symptoms

Common symptoms include:

Progressive pain

Swelling

and

Night pain.

Symptom Duration

Patients may have symptoms for approximately:

3–6 months

before the diagnosis is established.

Pain

Pain is often initially:

Intermittent

but becomes progressively more:

Persistent.

Night Pain

Increasing pain at:

Night

or at rest should raise concern for an aggressive:

Bone lesion.

Swelling

Local swelling may develop as the tumor enlarges and extends beyond the:

Cortex.

Pathologic Fracture

Weakening of bone by tumor may result in a:

Pathologic fracture.

This may occasionally be the:

Presenting event.

Physical Examination

The physical examination may initially be:

Normal

or demonstrate only:

Subtle abnormalities.

Soft-Tissue Mass

Once the tumor extends through the cortex into surrounding tissues, a palpable:

Soft-tissue mass

may develop.

Muscle Atrophy

Chronic pain and reduced use of the affected limb may lead to:

Muscle wasting

or

Atrophy.

Neurovascular Examination

Large lesions should be assessed carefully for involvement of adjacent:

Nerves

and

Blood vessels.

Laboratory Tests

There is no laboratory test specific for:

Undifferentiated sarcoma.

Alkaline Phosphatase

Serum:

Alkaline phosphatase

may be elevated when there is extensive:

Bone destruction or remodeling.

A normal level does not exclude:

Malignancy.

Imaging

Plain Radiographs

Primary bone lesions typically demonstrate an:

Aggressive lytic pattern.

Bone Destruction

Radiographs may show:

Moth-eaten

or

Permeative bone destruction.

These patterns suggest rapid tumor growth through:

Medullary bone.

Reactive Bone

Some lesions may demonstrate:

Reactive periosteal or osseous formation.

Cortical Destruction

Progressive tumor growth may produce:

Cortical breakthrough.

Soft-Tissue Extension

Large lesions may extend into surrounding:

Soft tissues.

Pathologic Fracture

Advanced bone destruction may predispose to:

Pathologic fracture.

Calcification

Occasional lesions contain small areas of:

Calcification.

However, organized tumor production of:

Osteoid

or

Cartilage matrix

suggests another diagnosis.

MRI

MRI is the preferred study for defining:

Local tumor extent.

It demonstrates:

Marrow involvement

Soft-tissue extension

Relationship to neurovascular structures

and involvement of:

Adjacent joints.

CT

CT can further characterize:

Cortical destruction

Mineralization

and selected areas of:

Complex anatomy.

Metastatic Staging

Because pulmonary metastasis is a major concern, staging generally includes:

CT of the chest.

Other imaging may include:

PET/CT

or

Bone scintigraphy

depending on the individual case and institutional protocol.

Biopsy

Definitive diagnosis requires:

Tissue biopsy.

Biopsy Planning

Biopsy should be performed after appropriate imaging and ideally planned by the:

Musculoskeletal oncology team

that will perform definitive:

Surgery.

The biopsy tract should be placed so that it can be removed during:

Tumor resection.

Pathological Findings

Grossly, these tumors may appear:

Firm

Fibrous

and

Fleshy.

Histology

Historical descriptions include a malignant:

Spindle-cell proliferation

with marked cellular:

Pleomorphism.

Storiform Pattern

Older descriptions of MFH emphasized a:

Storiform

or irregularly whorled arrangement of:

Spindle cells.

Histiocyte-Like Cells

Tumors may contain cells with:

Foamy cytoplasm

and

Multinucleated giant cells.

Modern Pathologic Principle

The diagnosis of an undifferentiated sarcoma is one of:

Exclusion.

Extensive pathologic evaluation is required to confirm that the tumor does not show convincing differentiation toward another:

Sarcoma lineage.

Osteoid or Chondroid Matrix

Production of definite malignant:

Osteoid

or

Chondroid matrix

by the tumor excludes a purely undifferentiated sarcoma and suggests diagnoses such as:

Osteosarcoma

or

Chondrosarcoma.

Differential Diagnosis

Important alternatives include:

Metastatic carcinoma

Multiple myeloma

Lymphoma

Osteosarcoma

Fibrosarcoma

and other:

Primary mesenchymal malignancies.

Metastatic Disease

In older adults, metastatic carcinoma is an important consideration for a destructive:

Bone lesion.

Multiple Myeloma

Myeloma may produce:

Lytic skeletal lesions

and should be considered particularly when multiple abnormalities or systemic findings are:

Present.

Lymphoma

Primary bone lymphoma may mimic a:

High-grade sarcoma

clinically and radiographically.

Osteosarcoma

Osteosarcoma is distinguished by malignant tumor production of:

Osteoid.

Fibrosarcoma

Fibrosarcoma is another malignant spindle-cell tumor that may resemble undifferentiated sarcoma but demonstrates more specific:

Fibroblastic differentiation.

Treatment

Management requires a:

Multidisciplinary sarcoma team.

Referral

Any patient suspected of having undifferentiated sarcoma should be referred promptly to a:

Musculoskeletal oncologist.

Treatment Goals

The principal goals are:

Local tumor control

and prevention or treatment of:

Metastatic disease.

Chemotherapy

Systemic chemotherapy may be used before and/or after surgery for selected:

High-grade bone sarcomas.

Neoadjuvant Chemotherapy

Preoperative chemotherapy may:

Treat micrometastatic disease

and facilitate subsequent:

Definitive surgery.

Adjuvant Chemotherapy

Postoperative chemotherapy may be used to reduce the risk of:

Systemic recurrence

depending on tumor type and oncology protocol.

Radiation Therapy

Primary undifferentiated sarcoma of bone has traditionally been considered relatively:

Radioresistant.

Soft-Tissue Sarcoma

Radiation therapy is used more frequently in:

Soft-tissue sarcoma

to improve:

Local control.

It may be given:

Preoperatively

or

Postoperatively

depending on tumor location, size, margins, and treatment plan.

Surgery

Surgery is central to treatment of localized:

Primary bone sarcoma.

Historical Treatment

Historically, tumors of the extremities were commonly treated with:

Amputation.

Limb Salvage

Modern oncologic surgery often permits:

Limb-sparing resection

when an adequate tumor-free margin can be obtained.

Reconstruction

After tumor resection, reconstruction may involve:

Endoprosthetic replacement

Allograft

or other forms of:

Biologic or prosthetic reconstruction.

Amputation

Amputation remains appropriate in selected cases when:

Clear margins cannot otherwise be achieved

or when limb salvage would leave unacceptable:

Function or complications.

Physical Therapy

Physical therapy plays an important role following:

Limb-salvage surgery

or

Amputation.

Rehabilitation Goals

Rehabilitation focuses on:

Range of motion

Strength

Gait

Prosthetic training

and restoration of:

Functional independence.

Follow-Up

Patients require long-term surveillance for:

Local recurrence

and

Pulmonary metastasis.

Pulmonary Surveillance

The lungs are a major site of hematogenous:

Metastasis.

Historical Surveillance Schedule

Older protocols have used:

Chest CT every 3 months for the first 2 years

followed by approximately:

Every 6 months for another 3 years.

Current surveillance schedules are individualized according to:

Tumor grade

Stage

and

Oncology guidelines.

Local Surveillance

Local recurrence is assessed by:

Physical examination

and serial:

Radiographs

MRI

or

CT

as appropriate.

Metal Implants

Metallic reconstruction may create imaging artifact, but modern:

MRI metal-artifact reduction techniques

and other modalities can still assist with:

Local surveillance.

Metastatic Disease

If pulmonary metastases develop, management may involve:

Medical oncology

and

Thoracic surgery

depending on:

Number

Location

and

Resectability of metastases.

Local Recurrence

Local recurrence requires reassessment by the:

Musculoskeletal oncology team

and may require additional:

Surgery

Radiation

or

Systemic therapy.

Prognosis

Undifferentiated sarcoma of bone is generally a:

High-grade malignancy.

Pulmonary Metastasis

Historical series have reported a risk of pulmonary metastasis exceeding:

50%.

The actual prognosis depends on:

Stage at diagnosis

Tumor size

Location

Response to therapy

and ability to obtain:

Wide surgical margins.

Prognostic Factors

Important factors include:

Presence of metastases at diagnosis

Tumor size

Anatomic location

Surgical margins

and response to:

Systemic treatment.

Complications

The major complications are:

Local recurrence

and

Metastatic disease.

Pulmonary Metastasis

The most important distant metastatic site is usually the:

Lung.

Pathologic Fracture

Advanced tumor destruction may also cause:

Pathologic fracture

which can complicate:

Surgical management.

Treatment-Related Complications

Potential complications include:

Wound problems

Infection

Implant failure

Chemotherapy toxicity

and functional limitations following:

Major reconstruction or amputation.

Patient Monitoring

Surveillance should assess for:

New local pain

New or enlarging mass

Pulmonary metastasis

and

Functional deterioration.

Clinical Summary

Typical patient: Middle-aged or older adult with progressive bone pain, swelling, or an enlarging soft-tissue mass.

Tumor behavior: High-grade mesenchymal malignancy with substantial risk of local recurrence and pulmonary metastasis.

Radiographs: Usually demonstrate an aggressive lytic, moth-eaten, or permeative lesion, sometimes with cortical destruction, soft-tissue extension, or pathologic fracture.

Local staging: MRI defines marrow and soft-tissue extent.

Metastatic staging: CT chest is particularly important because the lung is a common metastatic site.

Diagnosis: Requires carefully planned biopsy and exclusion of more specifically differentiated sarcomas.

Treatment: Multidisciplinary care with wide surgical resection, often combined with systemic chemotherapy for primary bone disease and selected use of radiation, particularly for soft-tissue tumors.

Surgery: Limb salvage is frequently possible; amputation is reserved for selected unreconstructible or oncologically unfavorable cases.

Main complications: Local recurrence and pulmonary metastasis.

Key Principle

Undifferentiated sarcoma is a rare, aggressive, high-grade mesenchymal malignancy of bone or soft tissue that is diagnosed only after more specific tumor differentiation has been:

Excluded.

Patients commonly present with:

Progressive pain, swelling, or a mass, and imaging often shows an aggressive:

Lytic destructive lesion.

Evaluation requires:

MRI for local staging, CT chest for pulmonary metastases, and carefully planned biopsy.

Treatment should be coordinated through a:

Musculoskeletal oncology team

and generally combines:

Wide surgical resection with appropriate systemic therapy, while radiation has an important role particularly in selected:

Soft-tissue sarcomas.

The major long-term threats are:

Local recurrence and pulmonary metastatic disease.